Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells

BackgroundEribulin mesylate (eribulin), a non-taxane microtubule dynamic inhibitor, has been widely used in the treatment of patients with advanced or metastatic breast cancer. The combined antitumor and anticancer stem cell (CSC) activities of eribulin with endocrine therapeutic agents have not yet been examined in breast cancer cells. We herein investigated the combined effects of eribulin and antiestrogens.MethodsA panel of eight breast cancer cell lines, including five estrogen receptor (ER)-positive and three ER-negative cell lines, was used. These cells were treated with eribulin and/or the antiestrogen, 4-hydroxytamoxifen or fulvestrant. Their growth inhibitory activities and effects on cell cycle progression, apoptosis, and the CSC population were investigated. CSCs were detected using the CD44/CD24/EpCAM, Aldefluor, and mammosphere assays.ResultsThe 50 % growth inhibitory concentrations of eribulin were 0.38–2.64 nM for the eight cell lines tested. Eribulin exhibited significant antitumor activity under estrogen-supplemented conditions in ER-positive breast cancer cells. The combined antitumor activity of eribulin with an antiestrogen was evaluated using the combination index. The combination index was 0.43–1.46 for ER-positive cell lines. The additive antitumor effect of eribulin with 4-OHT was only significant in MCF-7 cells. Eribulin induced the accumulation of G2/M and apoptosis, while antiestrogens induced the retardation of G1–S cell cycle and apoptosis, respectively. Estrogen markedly increased the proportion of CSCs, whereas antiestrogens inhibited increases in ER-positive cell lines. Moreover, eribulin decreased the proportion of CSCs in either ER-positive or ER-negative cell lines. The combined treatment of eribulin with an antiestrogen did not additively decrease the proportion of CSCs in ER-positive cell lines.DiscussionThe results of the present study demonstrated that eribulin had potent antitumor effects on estrogen-stimulated ER-positive breast cancer cells and the combined treatment of eribulin with an antiestrogen resulted in a weakly additive antitumor effect. We herein suggested for the first time that eribulin exhibited anti-CSC effects on either ER-positive or ER-negative breast cancer cells.

[1]  K. Sugimachi,et al.  Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Ohashi,et al.  Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial) , 2010, Breast Cancer Research and Treatment.

[3]  S. Puhalla,et al.  Treatment of Metastatic Breast Cancer: Chemotherapy , 2016 .

[4]  Mika Watanabe,et al.  Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype , 2010, BMC Cancer.

[5]  Y. Oda,et al.  Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro , 2014, Vascular cell.

[6]  Harikrishna Nakshatri,et al.  Breast cancer stem cells and intrinsic subtypes: controversies rage on. , 2009, Current stem cell research & therapy.

[7]  S. Ropero,et al.  Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma , 2004, Breast Cancer Research and Treatment.

[8]  Xintian Zhang,et al.  ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells , 2014, PloS one.

[9]  D. Derman,et al.  Treatment of metastatic breast cancer in estrogen receptor positive patients a randomized trial comparing tamoxifen alone versus tamoxifen plus CMF , 1982, Cancer.

[10]  B. Zee,et al.  Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Kurosumi,et al.  Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6 , 1999, British Journal of Cancer.

[12]  J. Wanders,et al.  Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes , 2012 .

[13]  N. Kanomata,et al.  Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells , 2012, Breast Cancer.

[14]  Chris Twelves,et al.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.

[15]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[16]  M. Kurosumi,et al.  A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice. , 1996, British Journal of Cancer.

[17]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[18]  E. Lander,et al.  Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling , 2010, Proceedings of the National Academy of Sciences.

[19]  F. X. Bosch,et al.  Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial , 1985, Cancer.

[20]  J. Kurebayashi,et al.  Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells , 2007, Cancer Chemotherapy and Pharmacology.

[21]  D. Radisky,et al.  Epithelial-mesenchymal transition and the stem cell phenotype. , 2008, Cell stem cell.

[22]  M. Wicha,et al.  Targeting breast cancer stem cells. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[24]  Y. Maehara,et al.  Postoperative chemo–endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor–positive stage II breast cancer , 1999, Breast Cancer Research and Treatment.

[25]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Kurebayashi,et al.  Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer , 2009, Cancer Chemotherapy and Pharmacology.

[27]  R. Beaulieu,et al.  ALDH1 as a functional marker of cancer stem and progenitor cells. , 2009, Stem cells and development.

[28]  M. Kurosumi,et al.  A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice. , 1995, British Journal of Cancer.

[29]  T. Yoshida,et al.  Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states , 2014, British Journal of Cancer.

[30]  H. Lee,et al.  patients: A Randomized Trial , 2013 .